Sinemet is a combination of Carbidopa, an inhibitor of the aromatic amino-acid
decarboxylase enzyme and Levodopa (L-Dopa), the metabolic precursor of Dopamine,
and it is used in the treatment of Parkinson's disease and Parkinson's syndrome.
Levodopa relieves the symptoms of Parkinson's disease presumably when it becomes
decarboxylased to Dopamine in the Brain. Carbidopa, which does not cross the
haematoencephalic barrier, is limited to only to the extra cerebral
decarboxylation of the Levodopa, thus providing a greater amount of Levodopa to
the Brain, for it's subsequent transformation into Dopamine. This eliminates the
need for large doses of Levodopa at frequent intervals. The lower dosage, on the
other hand, also reduces or eliminates many of the side effects attributed to
the Dopamine formed in extra cerebral tissue.
Used as prescribed and thanks to it's Levodopa content.
Sinemet improves general therapeutic response. It's lower dosage (approximately
80% less than that of Levodopa alone), provides effective and lasting plasmatic
concentrations of Levodopa. While it is known that pyridoxine hydrochlorate
(Vitamin B6), accelerates the periferic metabolism of Levodopa to Dopamine,
Carbidopa inhibits this action.
In an experiment in which patients received from 100 to 500mg
of pyridoxine on a daily basis, no alteration was seen in the anti- Parkinson
effect of the Levodopa, while they were treated with the Carbidopa and Levodopa
combination. It has been reported that the combination of Sinemet with the
inhibitors of the Monoamine Oxydase B (such as Deprenyl) increases the
effectiveness of Sinemet in patients with difficulty or slowness of movement.
to order (prescription
Sinemet usually reduces and in some cases even eliminates side effects
frequently suffered by patients undergoing Levodopa therapy- Anorexia, nausea,
vomiting. By reducing some of the side effects produced by Levodopa used alone,
Sinemet allows a greater number of patients to feel relief from the symptoms of
Sinemet provides fast therapeutic relief. Response to Sinemet
has been seen in as little as a day's time, often after a single dose. Sinemet
minimizes the need for the prolonged individual dosages required in Levodopa
treatment. Fully effective dosages are usually carried out within seven days, in
contrast to the weeks or months needed for Levodopa. Following the Sinemet
treatment, the plasmatic levels from Levodopa are five times greater than those
obtained with the same dosage of Levodopa applied on it's own.
Subjects responding to Levodopa can receive Sinemet treatment.
Sinemet reduces the fluctuations, often seen in the use of Levodopa on it's own,
in the patient's response. Sinemet may be used with other anti-Parkinson
medicine (see directions).
Information for Users
Sinemet is recommended for the treatment of Parkinson's disease and Parkinson's
syndrome. It is very useful for alleviating Parkinson's syndrome, especially
stiffness and bradykinesia. Sinemet is often useful in the treatment of tremors,
dysphasia, excessive saliva flow and postural instability, associated with
Parkinson's disease or syndrome. When therapeutic response to Levodopa by itself
is irregular, and the signs and symptoms of Parkinson's disease do not appear in
a uniformly controlled manner during the day, the substitution of Sinemet
usually proves to be effective in reducing this fluctuation.
By reducing certain side effects produced by the use of
Levodopa on it's own. Sinemet enables a greater number of patients to obtain an
adequate remission from the symptoms of Parkinson's disease. Sinemet is
recommended for patients suffering from Parkinson's disease or syndrome, who
have been taking Vitamin complexes containing B6.
Directions for Use
Sinemet, a combination of both Carbidopa and Levodopa, is available in tablet
form. Each Sinemet tablet contains 25mg Carbidopa and 250mg Levodopa.
The prescribed dosage depends on the individual needs of each patient and this
may require an adjustment of either the individual dosage, or the frequency of
it's administration. Treatment usually lasts seven days. Studies have shown that
the peripheric Dopa-decarboxylase is absorbed by the Carbidopa at a rate of
70-200 mg/ day. Patients who are given less Carbidopa are more likely to suffer
nausea and vomiting. Should such an undesired therapeutic effect take place more
often with Sinemet than with Levodopa alone, patients should be closely observed
during this period of adjustment to the dosage.
Involuntary movement especially can occur more rapidly with
Sinemet than with Levodopa. The onset of involuntary movement may require a
reduction of the dosage. In certain patients the blepharospasm may be a useful
early warning sign of excessive dosage. In the case of general anaesthetic,
Sinemet may be continued as long as the patient is allowed to take liquids and
medicines by mouth. If treatment is temporally interrupted, the regular daily
dosage can be administered as soon as the patient is able to take medicine
Patients who are Not Receiving Levodopa Treatment
The usual dosage is a half tablet of Sinemet once or twice per day. A half
tablet may increase this dosage either daily or on alternative days, until
optimum results are obtained.
Patients Being Treated with Levodopa
Levodopa treatment must be interrupted at least 12 hours (24 hours for delayed
action Levodopa preparations), prior to starting Sinemet treatment. It should be
taken into account that the daily dosage of Sinemet provides approximately 20%
of the previous Levodopa dosage. The recommended initial dosage for the majority
of patients who take more than 1500mg of Levodopa is one Sinemet tablet three or
four times daily. (For example, if the patient takes 4g of Levodopa per day, he
should not exceed 3 tablets of Sinemet per day). Patients taking Levodopa
together with another decarboxylase inhibitor should stop treatment at least 12
hours before beginning Sinemet treatment. We strongly recommend commencing
Sinemet treatment in order to supply the same amount of Levodopa contained in
the Levodopa/ decarboxylase inhibitors used previously.
Follow up Treatment
The majority of patients can continue with a dosage of 3 to 6 tablets per
day. There is no benefit to be had by increasing the dosage of Carbidopa beyond
8 tablets of Sinemet 25-250 per day, and the patient is warned against exceeding
this maximum dosage. Some patients may need a further dosage of Levodopa.
Results show that other anti-Parkinson medication (except Levodopa) may be
continued, although the dosage may need to be adjusted.
Sinemet is not recommended for patients with a known hypersensitivity to this
product, who suffer from close angle glaucoma, or who are in the acute phase of
myocardial infarction. Since Levodopa can also activate malignant melanoma, it
must not be used by patients with suspicious looking undiagnosed cutaneous
lesions, or with amanuensis of melanoma. Monoamine Oxydase A inhibitors and
Sinemet should not be taken at the same time, and treatment with this inhibitor
should be interrupted at least two weeks prior to beginning Sinemet treatment.
This product should not be taken by patients younger than 18 years of age,
during pregnancy or by nursing mothers.
Sinemet can be taken by patients who have undergone the treatment of Levodopa on
it's own, but such treatment of Levodopa must be interrupted at least 12 hours
before starting Sinemet. Sinemet must be substituted by a posology which
supplies approximately 20% of the Levodopa used previously (see directions for
use). Patients being treated with Sinemet must avoid taking additional dosages
of Levodopa, except under a doctor's strict supervision.
Sinemet is not recommended for the treatment of medicinal drug
induced extrapyramidal reactions. Patients known for psychotic behavior or
amanuensis should be treated with caution. As with Levodopa, Sinemet may cause
involuntary movements and mental disturbances. Patients with a history of
serious involuntary movements and psychotic conduct when treated with Levodopa
should be closely watched when Sinemet substitutes this. It is thought that such
reactions are due to an increase in cerebral Dopamine following the
administration of Levodopa and that the use of Sinemet may cause a relapse.
All patients should be carefully supervised regarding the
development of mental modifications, depression and suicidal tendencies, or
other such serious antisocial behavior. The most rapid appearance of high
Dopamine levels obtained with Sinemet treatment compared to that of Levodopa
alone might cause premature problems of movement. Such disturbances require a
reduction in the dosage of Sinemet.
Sinemet must be administered with care to asthma, renal,
hepatic and endocrine disorders. Attention should be paid to the administration
of Sinemet to patients who have a history of arrhythmias. In such patients,
cardial functions must be controlled with particular care during the period of
dosage adjustment. As with Levodopa, there is a chance of hemorrhaging with
patients with a history of peptic ulcers. A complex symptomatology has been
reported which is similar to the malignant neuroleptic syndrome with muscular
stiffness, high body temperature, mental modifications and the increase in the
silky creatine phosphate when the anti- Parkinson treatment is suddenly stopped.
Thus the patient should be attentively observed when the Sinemet dosage is
suddenly reduced or halted, especially if the patient is being treated with
As with Levodopa, in the case of prolonged treatment, it is
wise to undergo periodic tests, regarding the haematic formula and the hepatic,
renal and cardiocirculatory functions. Patients with chronic open angle glaucoma
can be treated with caution with Sinemet, providing intra-ocular pressure is
controlled and the patient is kept under close observation for signs of change
during the treatment.
Close attention should be paid when the following medicines are used
simultaneously with Sinemet. It has been proven that when Sinemet is taken
together with anti- hypertensive treatment, symptomatic hypertension can occur.
Thus, when Sinemet treatment is started, an adjustment in the dosage of the
anti- hypertension product may be necessary.
There have been reports, although admittedly few, concerning
undesirable reactions including hypertension and difficulty in movement, derived
from the concomitant use of tricyclic antidepressants and Sinemet.
Phenothiazines and butyrophenones may reduce the therapeutic effects of Levodopa.
It has also been reported that phenitoine and papaverine also
canceled out the beneficial effects of the latter. Patients who take this
medication with Sinemet should be carefully advised concerning the eventual loss
of its therapeutic properties. Given that Levodopa competes with certain amino
acids. Its absorption may be compromised in certain patients by a high protein
Side effects occurring to patients being treated with Sinemet are related to the
central neuropharmacological activity of Dopamine. These can usually be
diminished by a reduced dosage. The most common are- brusque, distonic movements
and/ or other involuntary movements. Muscular fibrillation and blepharospasm can
be considered as warning signs to reduce medication.
While Carbidopa allows for a higher Levodopa content in the
Brain, difficulty in movement has been seen with Sinemet at a lower dosage than
preparations containing only L-Dopa.
Other serious side effects are mental alterations, including
tendencies towards paranoia and psychotic behavior, depression accompanied or
not by suicidal tendencies, dementia. Convulsions are so rare as to not be
considered directly relating to Sinemet. Another common but none the less
unappealing side effect is nausea. Other less frequent side effects are cardia
unevenness and/ or palpitations, cases of orthostatic, hypertension,
bradykinesia (the on/ off phenomenon), anorexia, vomiting and vertigo.
Rare cases have been reported of gastrointestinal
hemorrhaging, duodenal ulcer, hypertension, phlebitis, leucopenia,
agranulcytosis, Thrombocytopenia, hemolytic and non hemolytic anemia. Positive
Comb's Tests have been carried out both with Sinemet and with Levodopa on it's
Lab tests have shown the following abnormalities- - Alkaline
phosphates, SGOT, SGPT, lactic- dehyrogenase, bilirubin, azotaemia, iodine left
in protein. Other side effects described in conjunction with Levodopa are the
Psychiatric: Ataxia, fainting, increased trembling of the
hands, muscular spasms, muscular cramp, trismus, activation of a latent hroner
Gastrointestinal- Constipation, diarrhea, abdominal pain and discomfort,
meteorism, hiccups, excess flow of saliva, bitter taste in the mouth, dryness of
the faeces, burning feeling in the tongue, dysphasia, teeth grinding.
Dermatological- Hot flushes, increased and/ or dark perspiration, alopecia, skin
Urogenital- Urine retention, incontinence, dark urine, priapism, haematuria.
Sense Organs- Blurred vision, diplopia, dilated pupils, oculogyric problems.
Metabolism- Weight loss, oedema.
Others- Weakness, listlessness, fatigue, headaches, hoarseness, uneasiness,
nervousness, irregular breathing rate, malignant neuroleptic syndrome.
In the Case of Overdose
In the case of severe overdose, the treatment is basically the same as with
severe overdose with treatment of Levodopa used alone. General first-aid
measures should be carried out in addition to immediate gastric lavage. The
application of liquid intravenously must be measured and air passages must be
kept clear. Adequate electrocardiograph control should be carried out to permit
the prompt detection of the development of the arrhythmia. The possibility that
the patient may have taken another medication at the same time as Sinemet should
be taken into account. As yet, there has been no research carried out regarding
dialysis and thus it's possible application in the case of overdose is unknown.
Vitamin B6 will not affect the action of Sinemet.
Available In boxes of 50 tablets, each contains 25mg of
Carbidopa and 250mg of Levodopa. Also available in boxes of 50 tablets each
containing 25mg of Carbidopa and 100mg of Levodopa.